193 related articles for article (PubMed ID: 33147278)
1. Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia.
Wan H; Selvaggio G; Pearlstein RA
PLoS One; 2020; 15(11):e0234946. PubMed ID: 33147278
[TBL] [Abstract][Full Text] [Related]
2. Cryo-EM Structure of K
Asai T; Adachi N; Moriya T; Oki H; Maru T; Kawasaki M; Suzuki K; Chen S; Ishii R; Yonemori K; Igaki S; Yasuda S; Ogasawara S; Senda T; Murata T
Structure; 2021 Mar; 29(3):203-212.e4. PubMed ID: 33450182
[TBL] [Abstract][Full Text] [Related]
3. Structural implications of hERG K
Helliwell MV; Zhang Y; El Harchi A; Du C; Hancox JC; Dempsey CE
J Biol Chem; 2018 May; 293(18):7040-7057. PubMed ID: 29545312
[TBL] [Abstract][Full Text] [Related]
4. Cryo-EM Structure of the Open Human Ether-à-go-go-Related K
Wang W; MacKinnon R
Cell; 2017 Apr; 169(3):422-430.e10. PubMed ID: 28431243
[TBL] [Abstract][Full Text] [Related]
5. Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation.
Pearlstein RA; MacCannell KA; Erdemli G; Yeola S; Helmlinger G; Hu QY; Farid R; Egan W; Whitebread S; Springer C; Beck J; Wang HR; Maciejewski M; Urban L; Duca JS
Curr Top Med Chem; 2016; 16(16):1792-818. PubMed ID: 26975508
[TBL] [Abstract][Full Text] [Related]
6. Towards a Structural View of Drug Binding to hERG K
Vandenberg JI; Perozo E; Allen TW
Trends Pharmacol Sci; 2017 Oct; 38(10):899-907. PubMed ID: 28711156
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of hERG Activation by Its Blocker: A Mechanism to Reduce Drug-Induced Proarrhythmic Risk.
Furutani K
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003453
[TBL] [Abstract][Full Text] [Related]
8. Automatic modeling of dynamic drug-hERG channel interactions using three voltage protocols and machine learning techniques: A simulation study.
Escobar F; Gomis-Tena J; Saiz J; Romero L
Comput Methods Programs Biomed; 2022 Nov; 226():107148. PubMed ID: 36170760
[TBL] [Abstract][Full Text] [Related]
9. Revealing Molecular Determinants of hERG Blocker and Activator Binding.
Dickson CJ; Velez-Vega C; Duca JS
J Chem Inf Model; 2020 Jan; 60(1):192-203. PubMed ID: 31880933
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiological characterization of the modified hERG
Zhang Y; Dempsey CE; Hancox JC
Physiol Rep; 2020 Oct; 8(20):e14568. PubMed ID: 33091232
[TBL] [Abstract][Full Text] [Related]
11. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
12. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
13. A novel hypothesis for the binding mode of HERG channel blockers.
Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
[TBL] [Abstract][Full Text] [Related]
14. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
15. Direct interaction of eag domains and cyclic nucleotide-binding homology domains regulate deactivation gating in hERG channels.
Gianulis EC; Liu Q; Trudeau MC
J Gen Physiol; 2013 Oct; 142(4):351-66. PubMed ID: 24043860
[TBL] [Abstract][Full Text] [Related]
16. New potential binding determinant for hERG channel inhibitors.
Saxena P; Zangerl-Plessl EM; Linder T; Windisch A; Hohaus A; Timin E; Hering S; Stary-Weinzinger A
Sci Rep; 2016 Apr; 6():24182. PubMed ID: 27067805
[TBL] [Abstract][Full Text] [Related]
17. Drug block of the hERG potassium channel: insight from modeling.
Stansfeld PJ; Gedeck P; Gosling M; Cox B; Mitcheson JS; Sutcliffe MJ
Proteins; 2007 Aug; 68(2):568-80. PubMed ID: 17444521
[TBL] [Abstract][Full Text] [Related]
18. Two mutations at different positions in the CNBH domain of the hERG channel accelerate deactivation and impair the interaction with the EAG domain.
Kume S; Shimomura T; Tateyama M; Kubo Y
J Physiol; 2018 Oct; 596(19):4629-4650. PubMed ID: 30086184
[TBL] [Abstract][Full Text] [Related]
19. Facilitation of
Furutani K; Tsumoto K; Chen IS; Handa K; Yamakawa Y; Sack JT; Kurachi Y
J Gen Physiol; 2019 Feb; 151(2):214-230. PubMed ID: 30674563
[TBL] [Abstract][Full Text] [Related]
20. Lidoflazine is a high affinity blocker of the HERG K(+)channel.
Ridley JM; Dooley PC; Milnes JT; Witchel HJ; Hancox JC
J Mol Cell Cardiol; 2004 May; 36(5):701-5. PubMed ID: 15135665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
